Evidence map›Paper›PMID 33662163›Full record

Trial reportThe European journal of neuroscience2021

A double-blind sham-controlled phase 1 clinical trial of tDCS of the dorsolateral prefrontal cortex in cocaine inpatients: Craving, sleepiness, and contemplation to change.

Pierre-Olivier Gaudreault, Akarsh Sharma, Abhishek Datta, Ester M Nakamura-Palacios, Sarah King, Pias Malaker, Ariella Wagner, Devarshi Vasa, Muhammad A Parvaz, Lucas C Parra and 2 more

Open access · greenAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph

Trial report in The European journal of neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A systematic review and meta-analysis of neuromodulation therapies for substance use disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. The neurobiology of drug addiction: cross-species insights into the dysfunction and recovery of the prefrontal cortex.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Pierre-Olivier GaudreaultPsychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.ORCID 0000-0002-9863-4436
Akarsh SharmaPsychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Abhishek DattaSoterix Medical Inc., New York City, NY, USA.
Ester M Nakamura-PalaciosProgram of Post-Graduation in Physiological Sciences, Federal University of Espirito Santo, Vitoria-ES, Brazil.ORCID 0000-0002-2196-2490
Sarah KingPsychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Pias MalakerPsychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Ariella WagnerPsychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Devarshi VasaPsychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Muhammad A ParvazPsychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Lucas C ParraBiomedical Engineering Department, City College of New York, New York City, NY, USA.
Nelly Alia-KleinPsychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Rita Z GoldsteinPsychiatry and Neuroscience Department, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Icahn School of Medicine at Mount Sinai · USCity College of New York · USSoterix Medical (United States) · USUniversidade Federal do Espírito Santo · BR

Funding

Atherosclerosis in cocaine addiction: imaging risk with PET/MRR01DA049547 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nelly Alia-Klein, Zahi A. Fayad · 2022 to 2026
$3.9M
Using event-related potentials to longitudinally track cue-induced craving incubation in cocaine addicted individualsR01DA041528 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOLDSTEIN, RITA Z · 2016 to 2020
$3.3M
Diagnostic and prognostic biomarkers for subtypes of addiction-related circuit dysfunctionR01DA047851 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI GOLDSTEIN, RITA Z, LISTON, CONOR M · 2019 to 2022
$2.4M
CIHRNIDA NIH HHS HHSN271201800035CNIDA NIH HHS R01 DA041528NIDA NIH HHS R01 DA047851NIDA NIH HHS R01 DA049547
6 · The paper itself

Abstract

Impaired inhibitory control accompanied by enhanced salience attributed to drug-related cues, both associated with function of the dorsolateral prefrontal cortex (dlPFC), are hallmarks of drug addiction, contributing to worse symptomatology including craving. dlPFC modulation with transcranial direct current stimulation (tDCS) previously showed craving reduction in inpatients with cocaine use disorder (CUD). Our study aimed at assessing feasibility of a longer tDCS protocol in CUD (15 versus the common five/10 sessions) and replicability of previous results. In a randomized double-blind sham-controlled protocol, 17 inpatients with CUD were assigned to either a real-tDCS (right anodal/left cathodal) or a sham-tDCS condition for 15 sessions. Following the previous report, primary outcome measures were self-reported craving, anxiety, depression, and quality of life. Secondary measures included sleepiness, readiness to change drug use, and affect. We also assessed cognitive function including impulsivity. An 88% retention rate demonstrated feasibility. Partially supporting the previous results, there was a trend for self-reported craving to decrease in the real-tDCS group more than the sham-group, an effect that would reach significance with 15 subjects per group. Quality of life and impulsivity improved over time in treatment in both groups. Daytime sleepiness and readiness to change drug use showed significant Group × Time interactions whereby improvements were noted only in the real-tDCS group. One-month follow-up suggested transient effects of tDCS on sleepiness and craving. These preliminary results suggest the need for including more subjects to show a unique effect of real-tDCS on craving and examine the duration of this effect. After replication in larger sample sizes, increased vigilance and motivation to change drug use in the real-tDCS group may suggest fortification of dlPFC-supported executive functions.

Indexed as

CocaineTranscranial Direct Current StimulationCravingDouble-Blind MethodHumansInpatientsPrefrontal CortexQuality of LifeSleepinessCocainecocaine use disorderdorsolateral prefrontal cortexdrug addictionself-reported cravingtranscranial direct current stimulation

Identifiers

PMID33662163
PMCPMC8089045
OpenAlexW3133627058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.